ERBB3 and neoplasm: The opportunity to target the triplet of tumor-restricted mutant-EGFRL858R–T790M, over-expressed HER3 and TAM-STING, offers the wider advantage to be more tumor-specific and immunogenic, and therefore less harmful long-term to non-tumoral tissues.